Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver

Liver International

Volumn 35, Issue 4, 2015, Pages 1274-1289

  Alzuguren, Pilar ^a   Hervas Stubbs, Sandra ^a   Gonzalez Aseguinolaza, Gloria ^a   Poutou, Joanna ^a   Fortes, Puri ^a   Mancheno, Uxua ^a   Bunuales, Maria ^a   Olagüe, Cristina ^a   Razquin, Nerea ^a   Van Rooijen, Nico ^b   Enguita, Monica ^a   Hernandez Alcoceba, Ruben ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adenovirus; B cells; CD4+ T cells; CD8+ T cells; Clodronate liposomes; Immunosuppression; Kupffer cells; Monoclonal antibodies; Neutralizing antibodies; NK cells

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIBODY; CLODRONIC ACID; DELTA MONOCLONAL ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MU MONOCLONAL ANTIBODY; OKT 4; RITUXIMAB; UNCLASSIFIED DRUG; ANTIBODY; BETA GALACTOSIDASE; IMMUNOSUPPRESSIVE AGENT; LUCIFERASE;

ADENOVIRIDAE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEK293 CELL LINE; HUMAN; HUMORAL IMMUNE DEFICIENCY; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO GENE TRANSFER; IN VIVO STUDY; KUPFFER CELL; LEUKOPENIA; LIPOSOMAL DELIVERY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MOUSE; NATURAL KILLER CELL; NONHUMAN; RAT; REPEATED DRUG DOSE; T CELL DEPLETION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LIVER; METABOLISM; PROCEDURES; REPORTER GENE; TIME; TRANSGENE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES; BETA-GALACTOSIDASE; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CLODRONIC ACID; FEMALE; GENE EXPRESSION REGULATION; GENES, REPORTER; GENETIC VECTORS; IMMUNITY, HUMORAL; IMMUNOSUPPRESSIVE AGENTS; LIVER; LUCIFERASES; LYMPHOCYTE DEPLETION; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84924505442     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12571     Document Type: Article

References (52)

1. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med 2013; 15: 65-77.
2. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-58.
3. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996; 3: 137-44.
4. Morral N, O'Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999; 96: 12816-21.
5. Tomita K, Sakurai F, Tachibana M, Mizuguchi H. Correlation between adenovirus-neutralizing antibody titer and adenovirus vector-mediated transduction efficiency following intratumoral injection. Anticancer Res 2012; 32: 1145-52.
6. Zaiss AK, Machado HB, Herschman HR. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 2009; 108: 778-90.
7. Sun C, Zhang Y, Feng L, et al. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine 2011; 29: 3837-41.
8. Thorner AR, Vogels R, Kaspers J, et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol 2006; 44: 3781-3.
9. Stephen SL, Montini E, Sivanandam VG, et al. Chromosomal integration of adenoviral vector DNA in vivo. J Virol 2010; 84: 9987-94.
10. Haisma HJ, Bellu AR. Pharmacological interventions for improving adenovirus usage in gene therapy. Mol Pharm 2011; 8: 50-5.
11. Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 2005; 12(Suppl. 1): S18-27.
12. Brunetti-Pierri N, Ng P. Helper-dependent adenoviral vectors for liver-directed gene therapy. Hum Mol Genet 2011; 20: R7-13.
13. Bangari DS, Mittal SK. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 2006; 6: 215-26.
14. Arruda VR, Favaro P, Finn JD. Strategies to modulate immune responses: a new frontier for gene therapy. Mol Ther 2009; 17: 1492-503.
15. Seregin SS, Appledorn DM, McBride AJ, et al. Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther 2009; 17: 685-96.
16. Fontanellas A, Hervas-Stubbs S, Mauleon I, et al. Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. Mol Ther 2010; 18: 754-65.
17. Jooss K, Turka LA, Wilson JM. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther 1998; 5: 309-19.
18. Kay MA, Meuse L, Gown AM, et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA 1997; 94: 4686-91.
19. Stein CS, Pemberton JL, van Rooijen N, Davidson BL. Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus. Gene Ther 1998; 5: 431-9.
20. Kuzmin AI, Galenko O, Eisensmith RC. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors. Mol Ther 2001; 3: 293-301.
21. Yang Y, Su Q, Grewal IS, et al. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol 1996; 70: 6370-7.
22. Haegel-Kronenberger H, Haanstra K, Ziller-Remy C, et al. Inhibition of costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys. Gene Ther 2004; 11: 241-52.
23. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719-27.
24. Robles-Carrillo L, Meyer T, Hatfield M, et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol 2010; 185: 1577-83.
25. Khare R, Chen CY, Weaver EA, Barry MA. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 2011; 11: 241-58.
26. Kuzmin AI, Finegold MJ, Eisensmith RC. Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther 1997; 4: 309-16.
27. Schiedner G, Hertel S, Johnston M, et al. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol Ther 2003; 7: 35-43.
28. McClane SJ, Chirmule N, Burke CV, Raper SE. Characterization of the immune response after local delivery of recombinant adenovirus in murine pancreas and successful strategies for readministration. Hum Gene Ther 1997; 8: 2207-16.
29. Ye X, Robinson MB, Pabin C, Batshaw ML, Wilson JM. Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse. Gene Ther 2000; 7: 1761-7.
30. Mazzolini G, Qian C, Narvaiza I, et al. Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. Hum Gene Ther 2000; 11: 113-25.
31. Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22: 1389-97.
32. Chentoufi AA, Nizet Y, Havaux X, et al. Differential effects of injections of anti-mu and anti-delta monoclonal antibodies on B-cell populations in adult mice: regulation of xenoreactive natural antibody-producing cells. Transplantation 1999; 68: 1728-36.
33. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994; 174: 83-93.
34. Perruche S, Zhang P, Liu Y, et al. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med 2008; 14: 528-35.
35. Snoeys J, Mertens G, Lievens J, et al. Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer. Mol Ther 2006; 13: 98-107.
36. Sangro B, Melero I, Qian C, Prieto J. Gene therapy of cancer based on interleukin 12. Curr Gene Ther 2005; 5: 573-81.
37. Muratore CS, Harty MW, Papa EF, Tracy TF Jr. Dexamethasone alters the hepatic inflammatory cellular profile without changes in matrix degradation during liver repair following biliary decompression. J Surg Res 2009; 156: 231-9.
38. Berglof A, Sandstedt K, Feinstein R, Bolske G, Smith CI. B cell-deficient muMT mice as an experimental model for Mycoplasma infections in X-linked agammaglobulinemia. Eur J Immunol 1997; 27: 2118-21.
39. Xu Z, Qiu Q, Tian J, et al. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med 2013; 19: 452-7.
40. Penuelas I, Mazzolini G, Boan JF, et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 2005; 128: 1787-95.
41. Lieber A, He CY, Meuse L, et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997; 71: 8798-807.
42. Moreau MF, Guillet C, Massin P, et al. Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol 2007; 73: 718-23.
43. Mian A, Guenther M, Finegold M, et al. Toxicity and adaptive immune response to intracellular transgenes delivered by helper-dependent vs. first generation adenoviral vectors. Mol Genet Metab 2005; 84: 278-88.
44. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011; 3: 76-99.
45. Rider DA, Havenith CE, de Ridder R, et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res 2007; 67: 9945-53.
46. Geng J, Wang X, Wei H, Sun R, Tian Z. Efficient attenuation of NK cell-mediated liver injury through genetically manipulating multiple immunogenes by using a liver-directed vector. J Immunol 2013; 190: 4821-9.
47. Peng Y, Falck-Pedersen E, Elkon KB. Variation in adenovirus transgene expression between BALB/c and C57BL/6 mice is associated with differences in interleukin-12 and gamma interferon production and NK cell activation. J Virol 2001; 75: 4540-50.
48. Yang Y, Xiang Z, Ertl HC, Wilson JM. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA 1995; 92: 7257-61.
49. Van Deusen KE, Rajapakse R, Bullock TN. CD70 expression by dendritic cells plays a critical role in the immunogenicity of CD40-independent, CD4+ T cell-dependent, licensed CD8+ T cell responses. J Leukoc Biol 2010; 87: 477-85.
50. Bunuales M, Garcia-Aragoncillo E, Casado R, et al. Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer. Hum Gene Ther 2012; 23: 1258-68.
51. Mazzolini G, Qian C, Xie X, et al. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther 1999; 6: 514-22.
52. Rodriguez-Madoz JR, Prieto J, Smerdou C. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther 2005; 12: 153-63.